Abstract: A process and product for a peat fuel composition which comprises dispersing peat loaded at about 30-50% by weight of the composition and normally containing 20-50% H.sub.2 O in a fuel oil mix which is 40-50% No. 6 and 10-20% No. 2 fuel oil. Alternatively, the final oil mix may have a viscosity between No. 6 fuel oil and No. 5 fuel oil or between 350 and 150 in seconds, Universal Saybolt (minimum) stability.
Type:
Grant
Filed:
February 5, 1982
Date of Patent:
March 20, 1984
Inventors:
Brooks M. Whitehurst, Donald F. Clemens
Abstract: This invention relates to a process for the production of 4a-aryldecahydroisoquinolines where the aryl group is selected as 3-methoxy phenyl. These compounds are morphine analogs and show utility similar to the known morphine, codeine, and thebaine. In this process particular novelty is asserted for the production of a nipecotic ester ethyl 4-(3'-methoxyphenyl)-1-methyl piperidine-3-carboxylate. Furthermore, novelty is asserted for the step of conversion of the nipecotates through cyclization to cis- or trans-tert-butyl 1,6-dioxo-4a-(3'-methoxyphenyl)-2-methyldecahydroisoquinoline-7-carboxylat e, which may also be easily converted to the keto amide, trans-1,6-dioxo-4a-(3'-methoxyphenyl)-2-methyldecahydroisoquinoline.
Type:
Grant
Filed:
March 16, 1981
Date of Patent:
March 6, 1984
Assignee:
The United States of America as represented by the Department of Health and Human Services
Inventors:
Henry Rapoport, Dwight D. Weller, Richard D. Cless
Abstract: A radioreceptor assay for benzodiazepines in saliva which comprises measuring the diminution of attachment of a known quantity of radio labeled benzodiazepine to a receptor carrier in the presence of an unknown quantity of unlabeled benzodiazepine in a known amount of human saliva. Benzodiazepines are selected from the following oft-utilized drugs which are also representative types of benzodiazepine; namely, diazepam (Valium), chlordiazepoxide (Librium), nitrazepam (Benzalin), oxazepam (Serax), flurazepam (Dalmane), and clorazepate.Competitive receptors suitable for the present benzodiazepine radioreceptor assay are from fresh rat frontal cortex. Utilizable receptors are whole brain cortex, human cortex, and striatum.
Type:
Grant
Filed:
March 30, 1981
Date of Patent:
February 14, 1984
Assignee:
The United States of America as represented by the Department of Health and Human Services
Abstract: A circular filter having separated inlet and outlet compartments such that cheese whey or the like is pumped into the vessel, is forced across a filter screen, and the filtered whey is discharged downstream for further processing. This invention incorporates (1) two rotating showers to clean the filter and (2) an outlet valve which recycles filtered whey for additional filtering and cleaning.
Abstract: The method of producing clinical assays for use of monoclonal antibodies in the diagnosis of Herpes simplex virus (HSV) infections and the differentiation of Herpes Simplex virus types 1 and 2 as a diagnostic kit for differentiating HSV-1 and HSV-2 utilizing clone 1D4 against HSV-1 and clone 3E1 against HSV-2.
Type:
Grant
Filed:
August 27, 1980
Date of Patent:
February 7, 1984
Assignee:
The United States of America as represented by the Department of Health and Human Services
Inventors:
Berge Hampar, Martin Zweig, Harvey Rabin, Conrad J. Heilman, Jr., Ralph F. Hopkins, III, Russell H. Neubauer
Abstract: An improved method for the preparation of .sup.125 I-labelled Protein A (.sup.125 I PA) of high specific and functional activity. .sup.125 I PA has been used in combination with purified rabbit IgG (immunoglobulin G) bound to a solid support to develop a competitive binding assay capable of detecting Protein A or human, rabbit and guinea pig IgG at the nanogram level. Additionally, .sup.125 I PA may be used to detect methotrexate, leucovorin and similar substances..sup.125 I PA has also been used to detect IgG anti-Forssman antibody bound to sheep erythrocytes and to line-1 and line-10 tumor cells and as an indirect assay for tumor associated antigen in the ascitic fluid of tumor-bearing guinea pigs.Additionally, an improved method of preparation of iodination of Protein A is utilized. This procedure used the Bolton-Hunter (1973) reagent of radioactive iodine in benzene which carrier is evaporated.
Type:
Grant
Filed:
October 1, 1981
Date of Patent:
February 7, 1984
Assignee:
The United States of America as represented by the Department of Health and Human Services
Abstract: A table top having the major part of its surface surrounding a central opening and including a plurality of radially disposed integrally formed locking means associated therewith for removably securing the same to a receptacle.
Abstract: In binary treatment with cis-dichlorodiamine-platinum(II) (or cisplatin) the preferred ratio of the present compound to cisplatin is about 10:1 with a range of about 10:1 to 1:10 in mg/kg of body weight.As to the variations in the formula on the left hand side of the formula, it may be varied as monodentate, such as cisplatin containing a single amine group proceeding from the ring, or bidentate, such as the present compound. The saturated cyclo ring may be C.sub.4 or C.sub.5 -C.sub.7 in addition to the present cyclohexane.The present platinum compound may be prepared by reacting the known L-aspartic acid, N-(phosphonacetyl-)disodium salt (PALA; NSC-224131), with dinitrato(1,2-diaminocyclohexane)platinum(II) (NSC-239851). This compound N-phosphonacetyl-L-asparato (1,2-diaminocyclohexane)platinum(II) may be combined in multiple drug regimen with substantially improved yield cures over the parent compounds.
Type:
Grant
Filed:
July 15, 1981
Date of Patent:
January 31, 1984
Assignee:
The United States of America as represented by the Department of Health and Human Services
Inventors:
Sandra J. Meischen, Glen R. Gale, Marion B. Naff
Abstract: The compounds are derived from aglycons which may be daunomycin, desmethoxy daunomycin, adriamycin and carminomycin. A preferred compound is ##STR1## (1) R'=H; R.sup.2 =OMe; X; Y (2) R'=OH; R.sup.2 =OMe; X; Y(3) R'=H; R.sup.2 =H; X; Y(4) R'=H; R.sup.2 =OH; X; YwhereX=I, Cl, Br, or F andY=OH or AcO (acetoxy)where Y is AcO or OH and R'=H and R.sup.2 =OMe.These compounds are effective showing high anti-leukemic activity against P388 murine leukemia.
Type:
Grant
Filed:
August 17, 1982
Date of Patent:
January 24, 1984
Assignee:
The United States of America as represented by the Department of Health and Human Services
Abstract: An improved energy-saving fuel additive for diesel engines and gasoline engines which comprises separate compositions which raise the flash point from about 6.degree. to 29.degree. C. In the case of the diesel additive, the following formulation is preferred:Elemental iron: 0.01%Methyl isobutyl ketone: 5.0%Picric acid: 1.5%Normal butyl alcohol: 20.0%Kerosene: 73.0%Nitrobenzene: 0.08%Primene 81R: 0.05%The composition of the agent for gasoline to high flash point is somewhat different and may be noted as follows:Copper carbonate hydroxide: 0.02%Methyl isobutyl ketone: 5.0%Normal butyl alcohol: 20.0%Kerosene: 73.0%Picric acid: 1.5%Nitrobenzene: 0.08%Primene 81R: 0.
Abstract: An improvement in the production of methotrexate as set out in Ellard U.S. Pat. No. 4,080,325. It has been found that magnesium oxide facilitates the coupling reaction by acting as an acid acceptor. The dense grade of magnesium oxide is preferred in molar proportions of 2 to 4 moles of magnesium oxide per mole of 2,4-diamino-6-hydroxymethylpteridine. Further, the triphenylphosphine oxide which is generated by hydrolysis of the protecting groups is removed from the reaction stream by utilization of toluene or BTX-type solvents.
Type:
Grant
Filed:
December 11, 1981
Date of Patent:
December 20, 1983
Assignee:
The United States of America as represented by the Secretary of the Department of Health and Human Services
Abstract: A novel method and composition are provided for the replication and expression of exogenous genes in eukaryotic cells. A segment of a papilloma virus genome capable of extrachromosomal replication is linked to the foreign gene(s) using recombinant DNA techniques to provide a biologically functional replicon with a desired phenotypical property. The replicon is inserted into a eukaryotic cell by transformation, and the isolation of transformant provides cells for replication and expression of the DNA molecules present in the modified plasmid. The transforming region of the bovine papilloma virus provides a unique vector in that it provides both the capability of autonomous extrachromosomal replication but also the malignant transformed phenotype. Thus, genes which of themselves provide no selectable phenotypical property can be conveniently and efficiently introduced into eukaryotic cells and the transformants selected.
Type:
Grant
Filed:
December 31, 1980
Date of Patent:
December 6, 1983
Assignee:
The United States of America as represented by the Department of Health and Human Services
Inventors:
Peter M. Howley, Nava Sarver, Ming-Fan Law
Abstract: A method of producing acrylamide from acrylonitrile in the presence of a metallic conversion catalyst which comprises contacting a water-in-oil emulsion of acrylonitrile which is contained in the dispersed aqueous phase of the emulsion under conditions whereby a substantial portion of the acrylonitrile is converted to acrylamide which remains in the aqueous phase of the emulsion.
Abstract: Polymer-bound dyes have been prepared by the diazotization of high polymeric [NP(OC.sub.6 H.sub.5).sub.x - (OC.sub.6 H.sub.4 NH.sub.2 -p).sub.y ]n, followed by coupling to phenol, .beta.-naphthol, 6'-NaO.sub.3 S-.beta.-naphthol, and p-aminophenylnaphthalene. These reactions were preceded by model compound studies with the cyclic trimer [NP(OC.sub.6 H.sub.4 NH.sub.2 -p-).sub.2 ].sub.3. In both cases, the aminophenoxy units were generated by reduction of 4-nitrophenoxy groups with the use of PtO.sub.2 and hydrogen. The phosphazene skeleton was unaffected by the reduction, diazotization, and diazo coupling processes. The physical characteristics of the trimers and high polymers are described.
Type:
Grant
Filed:
June 16, 1982
Date of Patent:
October 25, 1983
Assignee:
The United States of America as represented by the Department of Health and Human Services
Abstract: In a short total synthesis of morphinan compounds, derivatives of 1-benzyl-1,2,3,4-tetrahydroisoquinoline are produced. Certain of these compounds, although highly aromatic and functionalized, can be optically resolved. The optically active enantiomers can serve as important intermediates for both natural and unnatural opioids.
Type:
Grant
Filed:
May 20, 1981
Date of Patent:
October 18, 1983
Assignee:
The United States of America as represented by the Department of Health and Human Services
Abstract: Naturally occurring iridoids provide the starting material for a unique synthesis sequence to produce prostaglandin intermediates. The iridoid lactone is hydrogenated, converted to an acetal, and rings opened to introduce the carbonyl octenyl side chain in six steps. The intermediate can be converted to prostaglandin as previously demonstrated.
Type:
Grant
Filed:
September 25, 1981
Date of Patent:
October 18, 1983
Assignee:
Research Foundation of the City University of New York
Inventors:
William F. Berkowitz, Satish C. Choudhry, Joseph A. Hrabie